These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30599401)

  • 1. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators.
    Fassio A; Adami G; Gatti D; Orsolini G; Giollo A; Idolazzi L; Benini C; Vantaggiato E; Rossini M; Viapiana O
    Int Immunopharmacol; 2019 Feb; 67():487-489. PubMed ID: 30599401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis.
    Adami G; Orsolini G; Adami S; Viapiana O; Idolazzi L; Gatti D; Rossini M
    Calcif Tissue Int; 2016 Oct; 99(4):360-4. PubMed ID: 27307275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study.
    Fassio A; Adami G; Giollo A; Viapiana O; Malavolta N; Saviola G; Bortolotti R; Idolazzi L; Bertoldo F; Rossini M; Gatti D
    Calcif Tissue Int; 2020 Apr; 106(4):371-377. PubMed ID: 31897527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
    Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethö Z; Váncsa A; Bodnár N; Csomor P; Hamar A; Bodoki L; Bhattoa HP; Juhász B; Nagy Z; Hodosi K; Karosi T; FitzGerald O; Szücs G; Szekanecz Z; Szamosi S; Szántó S
    Clin Rheumatol; 2020 Jan; 39(1):167-175. PubMed ID: 31522318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
    Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
    Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
    Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
    Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis.
    Orsolini G; Adami G; Adami S; Viapiana O; Idolazzi L; Gatti D; Rossini M
    Calcif Tissue Int; 2016 Jun; 98(6):580-5. PubMed ID: 26887973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.
    de Rooy DP; Yeremenko NG; Wilson AG; Knevel R; Lindqvist E; Saxne T; Krabben A; Leijsma MK; Daha NA; Tsonaka S; Zhernakova A; Houwing-Duistermaat JJ; Huizinga TW; Toes RE; Baeten DL; Brouwer E; van der Helm-van Mil AH
    Ann Rheum Dis; 2013 May; 72(5):769-75. PubMed ID: 23041840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
    Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of correlation of level of expression of Wnt signaling pathway inhibitors sclerostin and dickkopf-1 with disease activity and severity in rheumatoid arthritis patients.
    Singh A; Gupta MK; Mishra SP
    Drug Discov Ther; 2019; 13(1):22-27. PubMed ID: 30880318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
    Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.